Franklin Biotechnology Discovery Fund Advisor Class (FTDZX)

142.21
Net Asset Value
-0.75%
1 Day
-7.51%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
No Load
Sales Expenses
0.79%
Expense Ratio
Above Average
Morningstar Risk Rating™
Investment Objective The investment seeks capital appreciation. Under normal market conditions- the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities. In addition to its investments in biotechnology companies- the fund may also invest up to 20% of its net assets in equity or debt securities of any type of issuer. It is non-diversified.

Performance

1 month-6.09% 3 years-1.49%
3 months-12.06% 5 years+7.64%
1 year-2.97% Since inception+15.51%
Data through --

Peer Comparisonvs. Health

 FTDZXCategory
Performance 5-yr return+7.64%+14.62%
Expense ratio0.79%1.28%
Risk 5 year sharpe ratio0.400.77
Net assets$1.2B$3.2B
Average market cap$9.3B$28.9B
Average P/E--26.9
Portfolio turnover27%27%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyFranklin Templeton Investments
Fund manager & tenureEvan McCulloch / 21 Years
Minimal initial investment$100,000.00
Minimum IRA investment--

Holdings

U.S. stock95.29%
International stock3.84%
Fixed income0.82%
Cash0.05%
Other0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
ALXN Alexion Pharmaceuticals Inc8.11%
CELG Celgene6.85%
BIIB Biogen6.10%
VRTX Vertex Pharmaceuticals Inc6.04%
ILMN Illumina Inc5.81%
REGN Regeneron Pharmaceuticals4.09%
GILD Gilead Sciences3.39%
AMGN Amgen3.39%
NBIX Neurocrine Biosciences Inc3.00%
ARRY Array Biopharma Inc2.74%